| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Jan 24, 2012CoreValve U.S. Trial to Continue Enrolling Patients in High Risk Study, and Will Maintain Therapy Access to Extreme Risk Patients via Continued Access Phase of Trial
MINNEAPOLIS, Jan 24, 2012 (BUSINESS WIRE) --Medtronic, Inc. (NYSE: MDT) today announced it has completed patient enrollment in the extreme risk study in its CoreValve U.S. Pivotal Trial. The...
-
Jan 23, 2012
MINNEAPOLIS--(BUSINESS WIRE)--Jan. 23, 2012-- Medtronic, Inc. (NYSE:MDT) announced today that it has received 510(k) clearance from the Food and Drug Administration (FDA) for the Aquamantys® SBS...
-
Jan 17, 2012Enhanced Medical Device to Repair Abdominal Aortic Aneurysms Without Open Surgery Expands Physicians’ Options for Treating ‘Silent Killer’
MINNEAPOLIS--(BUSINESS WIRE)--Jan. 17, 2012-- Medtronic Inc. (NYSE: MDT) today announced the CE (Conformité Européenne) mark and international launch of the Endurant®II AAA Stent Graft System,...
-
Jan 17, 2012Enhanced Medical Device to Repair Abdominal Aortic Aneurysms Without Open Surgery Expands Physicians' Options for Treating 'Silent Killer'
MINNEAPOLIS, Jan 17, 2012 (BUSINESS WIRE) --Medtronic Inc. (NYSE: MDT) today announced the CE (Conformité Européenne) mark and international launch of the Endurant(R) II AAA Stent Graft System,...
-
Jan 4, 2012mySentry Allows Caregivers to See Real-Time Insulin Pump Information and Glucose Trends from Another Room
MINNEAPOLIS--(BUSINESS WIRE)--Jan. 4, 2012-- Today, Medtronic, Inc. (NYSE:MDT) announced U.S. Food and Drug Administration (FDA) approval and U.S. market launch of the first-of-its-kind...